Analyzing the Global CNS Market
The CNS market at a global scale is one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms remain favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs.
The CNS disorders market may be segmented into numerous subcategories, including Alzheimer's disease (AD), epilepsy, insomnia, major depressive disorder (MDD), Parkinson's disease (PD), migraine, schizophrenia, attention-deficit hyperactivity disorder (ADHD), bipolar disorder among others. Antipsychotics were the largest CNS drug class. Patent expirations of key brands Seroquel and Zyprexa will form the main resistors to segmental growth through 2016. The CNS sector has struggled recently, as product classes that have dominated treatment areas have come under increasing pricing pressure from generics or have been plagued with safety concerns.
The top players in the CNS market at a global level at this time are Johnson & Johnson, Pfizer, GSK, Eli Lilly, etc. Several of the top-selling CNS drugs are likely to lose patent protection in the next three years enabling generics to flood the market and erode the sales figures of pharma companies. The CNS portfolios of J&J and GSK are particularly vulnerable as each will each face generic competition for three of their leading CNS drugs.
Aruvians Rsearch analyzes the Global CNS Market in its research offering Analyzing the Global CNS Market. The report is a comprehensive analysis of the global CNS industry.
The report begins with an introduction to CNS disorders. We analyze the basic CNS disorders such as ADHD, Alzheimer's disease, epilepsy, insomnia, major depressive disorder (MDD), migraine, Parkinson's disease, and Schizophrenia.
Moving to the next section, we analyze the global CNS market through a market overview and an analysis of the market by CNS drug classes. We also analyze the industry through an industry segmentation and an analysis of the leading industry products. We look at the sales figures of the leading products in the industry.
With the rapid advances in technology, it is no wonder that there are now many novel emerging drug classes available for the treatment of CNS disorders. Some of these novel emerging drug classes for CNS disorder treatment are analyzed in our report.
Competition in the industry is analyzed in the report, following which we move on to the analysis of the major players in the global CNS industry. Players in the industry are analyzed through a corporate profile, an analysis of their major business segments, their major products and services offered, and an analysis of their presence in the CNS market. We also look at their CNS R&D pipeline, along with the company strategy for future growth in the CNS industry. A SWOT analysis of the players completes the analysis of the major industry contributors.
Future perspective of the global CNS market completes this in-depth profile of the global CNS market from Aruvians Rsearch.
The CNS disorders market may be segmented into numerous subcategories, including Alzheimer's disease (AD), epilepsy, insomnia, major depressive disorder (MDD), Parkinson's disease (PD), migraine, schizophrenia, attention-deficit hyperactivity disorder (ADHD), bipolar disorder among others. Antipsychotics were the largest CNS drug class. Patent expirations of key brands Seroquel and Zyprexa will form the main resistors to segmental growth through 2016. The CNS sector has struggled recently, as product classes that have dominated treatment areas have come under increasing pricing pressure from generics or have been plagued with safety concerns.
The top players in the CNS market at a global level at this time are Johnson & Johnson, Pfizer, GSK, Eli Lilly, etc. Several of the top-selling CNS drugs are likely to lose patent protection in the next three years enabling generics to flood the market and erode the sales figures of pharma companies. The CNS portfolios of J&J and GSK are particularly vulnerable as each will each face generic competition for three of their leading CNS drugs.
Aruvians Rsearch analyzes the Global CNS Market in its research offering Analyzing the Global CNS Market. The report is a comprehensive analysis of the global CNS industry.
The report begins with an introduction to CNS disorders. We analyze the basic CNS disorders such as ADHD, Alzheimer's disease, epilepsy, insomnia, major depressive disorder (MDD), migraine, Parkinson's disease, and Schizophrenia.
Moving to the next section, we analyze the global CNS market through a market overview and an analysis of the market by CNS drug classes. We also analyze the industry through an industry segmentation and an analysis of the leading industry products. We look at the sales figures of the leading products in the industry.
With the rapid advances in technology, it is no wonder that there are now many novel emerging drug classes available for the treatment of CNS disorders. Some of these novel emerging drug classes for CNS disorder treatment are analyzed in our report.
Competition in the industry is analyzed in the report, following which we move on to the analysis of the major players in the global CNS industry. Players in the industry are analyzed through a corporate profile, an analysis of their major business segments, their major products and services offered, and an analysis of their presence in the CNS market. We also look at their CNS R&D pipeline, along with the company strategy for future growth in the CNS industry. A SWOT analysis of the players completes the analysis of the major industry contributors.
Future perspective of the global CNS market completes this in-depth profile of the global CNS market from Aruvians Rsearch.
A. EXECUTIVE SUMMARY
B. INTRODUCTION TO CNS DISORDERS
B.1 What is CNS?
B.2 CNS Disorders
B.2.1 Attention-Deficit Hyperactivity Disorder
B.2.2 Alzheimer's Disease
B.2.3 Epilepsy
B.2.4 Insomnia
B.2.5 Major Depressive Disorder (MDD)
B.2.6 Migraine
B.2.7 Parkinson's Disease
B.2.8 Schizophrenia
C. GLOBAL CNS MARKET
C.1 Market Overview
C.2 Top CNS Products
C.3 Impact of Patent Expirations
C.4 CNS Drugs Pipeline
C.5 Industry R&D
D. FACTORS IMPACTING THE MARKET
D.1 Growth Drivers
D.2 Challenges Facing the Market
E. PERFORMANCE OF VARIOUS DRUG CLASSES
E.1 Overview
E.2 Antidepressants
E.2.1 Cymbalta (duloxetine)
E.2.2 Effexor (venlafaxine)
E.2.3 Lexapro (escitalopram)
E.3 Anti-epileptics
E.3.1 Lamictal (lamotrigine)
E.3.2 Lyrica (pregabalin)
E.3.3 Keppra/Keppra XR (levetiracetam)
E.4 Anti-Alzheimer’s Disease Drugs
E.4.1 Aricept (donepezil)
E.4.2 Exelon (rivastigmine)
E.4.3 Namenda (memantine)
E.5 Anti-Migraine Drugs
E.5.1 Maxalt (rizatriptan)
E.5.2 Imigran/Imitrex (sumatriptan)
E.5.3 Zomig (zolmitriptan)
E.6 Antipsychotics
E.6.1 Abilify (aripiprazole)
E.6.2 Risperdal (risperidone)
E.6.3 Seroquel (quetiapine)
E.6.4 Zyprexa (olanzapine)
E.7 Anti-Parkinson’s Disease Drugs
E.7.1 Comtan/Stalevo (carbidopa/levodopa/entacapone)
E.7.2 Mirapex/Sifrol (pramipexole)
E.7.3 Requip (ropinirole)
E.8 Hypnotics & Sedatives
E.8.1 Ambien/Stilnox (zolpidem)
E.8.2 Lunesta (eszopiclone)
E.9 Psychostimulants
E.9.1 Adderall/Adderall XR (amphetamine/dexamfetamine)
E.9.2 Concerta (methylphenidate)
E.9.3 Provigil (modafinil)
E.9.4 Vyvanse (lisdexamfetamine)
F. UPCOMING/RECENTLY DEVELOPED CNS DRUGS
F.1 Overview
F.2 Bapineuzumab
F.3 Botox (onabotulinumtoxin-A)
F.4 IPX066
F.5 Latuda
F.6 Levadex
F.7 LY2216684/NERI
F.8 MK-4305
F.9 Potiga/Trobalt
F.10 RG1678/RO4917838
F.11 Silenor
F.12 Solanezumab
F.13 Stedesa
F.14 TC-5214 (S-mecamylamine)
F.15 Telcagepant
F.16 Valdoxan/Thymanax
G. GLOBAL CNS DRUGS MARKET FORECAST
H. COMPETITION IN THE INDUSTRY
I. LEADING INDUSTRY CONTRIBUTORS
I.1 AstraZeneca
I.1.1 Corporate Profile
I.1.2 Business Segment Analysis
I.1.3 Presence in the CNS Market
I.1.4 Seroquel
I.1.5 Zomig
I.1.6 Research & Development
I.1.7 Company Strategy in the Global CNS Market
I.1.8 SWOT Analysis
I.2 Eli Lilly
I.2.1 Corporate Profile
I.2.2 Business Segment Analysis
I.2.3 Presence in the CNS Market
I.2.4 Zyprexa
I.2.5 Cymbalta
I.2.6 Strattera
I.2.7 Research & Development
I.2.8 Company Strategy in the Global CNS Market
I.2.9 SWOT Analysis
I.3 GlaxoSmithKline
I.3.1 Corporate Profile
I.3.2 Business Segment Analysis
I.3.3 Presence in the CNS Market
I.3.4 Lamictal
I.3.5 Requip
I.3.6 Seroxat/Paxil
I.3.7 Research & Development
I.3.8 Company Strategy in the Global CNS Market
I.3.9 SWOT Analysis
I.4 Johnson & Johnson
I.4.1 Corporate Profile
I.4.2 Business Segment Analysis
I.4.3 Presence in the CNS Market
I.4.4 Concerta
I.4.5 Razadyne/Reminyl
I.4.6 Risperdal Consta
I.4.7 Risperdal
I.4.8 Topamax
I.4.9 Research & Development
I.4.10 Company Strategy in the Global CNS Market
I.4.11 SWOT Analysis
I.5 Pfizer
I.5.1 Corporate Profile
I.5.2 Business Segment Analysis
I.5.3 Presence in the CNS Market
I.5.4 Lyrica
I.5.5 Effexor
I.5.6 Zeldox/Geodon
I.5.7 Research & Development
I.5.8 Company Strategy in the Global CNS Market
I.5.9 SWOT Analysis
J. GLOSSARY OF TERMS
K. RESEARCH METHODOLOGY
B. INTRODUCTION TO CNS DISORDERS
B.1 What is CNS?
B.2 CNS Disorders
B.2.1 Attention-Deficit Hyperactivity Disorder
B.2.2 Alzheimer's Disease
B.2.3 Epilepsy
B.2.4 Insomnia
B.2.5 Major Depressive Disorder (MDD)
B.2.6 Migraine
B.2.7 Parkinson's Disease
B.2.8 Schizophrenia
C. GLOBAL CNS MARKET
C.1 Market Overview
C.2 Top CNS Products
C.3 Impact of Patent Expirations
C.4 CNS Drugs Pipeline
C.5 Industry R&D
D. FACTORS IMPACTING THE MARKET
D.1 Growth Drivers
D.2 Challenges Facing the Market
E. PERFORMANCE OF VARIOUS DRUG CLASSES
E.1 Overview
E.2 Antidepressants
E.2.1 Cymbalta (duloxetine)
E.2.2 Effexor (venlafaxine)
E.2.3 Lexapro (escitalopram)
E.3 Anti-epileptics
E.3.1 Lamictal (lamotrigine)
E.3.2 Lyrica (pregabalin)
E.3.3 Keppra/Keppra XR (levetiracetam)
E.4 Anti-Alzheimer’s Disease Drugs
E.4.1 Aricept (donepezil)
E.4.2 Exelon (rivastigmine)
E.4.3 Namenda (memantine)
E.5 Anti-Migraine Drugs
E.5.1 Maxalt (rizatriptan)
E.5.2 Imigran/Imitrex (sumatriptan)
E.5.3 Zomig (zolmitriptan)
E.6 Antipsychotics
E.6.1 Abilify (aripiprazole)
E.6.2 Risperdal (risperidone)
E.6.3 Seroquel (quetiapine)
E.6.4 Zyprexa (olanzapine)
E.7 Anti-Parkinson’s Disease Drugs
E.7.1 Comtan/Stalevo (carbidopa/levodopa/entacapone)
E.7.2 Mirapex/Sifrol (pramipexole)
E.7.3 Requip (ropinirole)
E.8 Hypnotics & Sedatives
E.8.1 Ambien/Stilnox (zolpidem)
E.8.2 Lunesta (eszopiclone)
E.9 Psychostimulants
E.9.1 Adderall/Adderall XR (amphetamine/dexamfetamine)
E.9.2 Concerta (methylphenidate)
E.9.3 Provigil (modafinil)
E.9.4 Vyvanse (lisdexamfetamine)
F. UPCOMING/RECENTLY DEVELOPED CNS DRUGS
F.1 Overview
F.2 Bapineuzumab
F.3 Botox (onabotulinumtoxin-A)
F.4 IPX066
F.5 Latuda
F.6 Levadex
F.7 LY2216684/NERI
F.8 MK-4305
F.9 Potiga/Trobalt
F.10 RG1678/RO4917838
F.11 Silenor
F.12 Solanezumab
F.13 Stedesa
F.14 TC-5214 (S-mecamylamine)
F.15 Telcagepant
F.16 Valdoxan/Thymanax
G. GLOBAL CNS DRUGS MARKET FORECAST
H. COMPETITION IN THE INDUSTRY
I. LEADING INDUSTRY CONTRIBUTORS
I.1 AstraZeneca
I.1.1 Corporate Profile
I.1.2 Business Segment Analysis
I.1.3 Presence in the CNS Market
I.1.4 Seroquel
I.1.5 Zomig
I.1.6 Research & Development
I.1.7 Company Strategy in the Global CNS Market
I.1.8 SWOT Analysis
I.2 Eli Lilly
I.2.1 Corporate Profile
I.2.2 Business Segment Analysis
I.2.3 Presence in the CNS Market
I.2.4 Zyprexa
I.2.5 Cymbalta
I.2.6 Strattera
I.2.7 Research & Development
I.2.8 Company Strategy in the Global CNS Market
I.2.9 SWOT Analysis
I.3 GlaxoSmithKline
I.3.1 Corporate Profile
I.3.2 Business Segment Analysis
I.3.3 Presence in the CNS Market
I.3.4 Lamictal
I.3.5 Requip
I.3.6 Seroxat/Paxil
I.3.7 Research & Development
I.3.8 Company Strategy in the Global CNS Market
I.3.9 SWOT Analysis
I.4 Johnson & Johnson
I.4.1 Corporate Profile
I.4.2 Business Segment Analysis
I.4.3 Presence in the CNS Market
I.4.4 Concerta
I.4.5 Razadyne/Reminyl
I.4.6 Risperdal Consta
I.4.7 Risperdal
I.4.8 Topamax
I.4.9 Research & Development
I.4.10 Company Strategy in the Global CNS Market
I.4.11 SWOT Analysis
I.5 Pfizer
I.5.1 Corporate Profile
I.5.2 Business Segment Analysis
I.5.3 Presence in the CNS Market
I.5.4 Lyrica
I.5.5 Effexor
I.5.6 Zeldox/Geodon
I.5.7 Research & Development
I.5.8 Company Strategy in the Global CNS Market
I.5.9 SWOT Analysis
J. GLOSSARY OF TERMS
K. RESEARCH METHODOLOGY
LIST OF FIGURES
Figure 1: Stages of Alzheimer's Disease
Figure 2: Treatment Processes for Migraine
Figure 3: Symptoms of Schizophrenia
Figure 4: Treatment Types for Schizophrenia
Figure 5: Upcoming/Recently Launched CNS Drugs
Figure 1: Stages of Alzheimer's Disease
Figure 2: Treatment Processes for Migraine
Figure 3: Symptoms of Schizophrenia
Figure 4: Treatment Types for Schizophrenia
Figure 5: Upcoming/Recently Launched CNS Drugs
LIST OF TABLES
Table 1: Epidemiology of ADHD in Adults, 2011-2017
Table 2: Epidemiology of ADHD in Children, 2011-2017
Table 3: Epidemiology of ADHD in Adults, 2011-2017
Table 4: Epidemiology of ADHD in Children, 2011-2017
Table 5: Prevalence of Alzheimer’s Disease in Select Countries, 2011
Table 6: Epidemiology of Alzheimer's Disease, 2011-2017
Table 7: Prevalence of Epilepsy in Select Countries, 2011
Table 8: Epidemiology of Epilepsy, 2011-2017
Table 9: Prevalence of Insomnia in Select Countries, 2011
Table 10: Epidemiology of Insomnia, 2011-2017
Table 11: Prevalence of Major Depressive Disorders in Select Countries, 2011
Table 12: Epidemiology of Major Depressive Disorders, 2011-2017
Table 13: Prevalence of Migraine in Select Countries, 2011
Table 14: Epidemiology of Migraine, 2011-2017
Table 15: Prevalence of Parkinson’s Disease in Select Countries, 2011
Table 16: Epidemiology of Parkinson’s Disease, 2011-2017
Table 17: Prevalence of Schizophrenia in Select Countries, 2011
Table 18: Epidemiology of Schizophrenia, 2011-2017
Table 19: Performance of the CNS Market by Region (2006-2011)
Table 20: Top 10 CNS Products in 2011
Table 21: Patent Expiries of Key CNS Drugs/Brands
Table 22: Global CNS Pipeline
Table 23: Performance of Various CNS Drug Classes, 2011
Table 24: Sales of Top Antidepressant Products in 2011
Table 25: Sales of Top Anti-epileptics Products in 2011
Table 26: Sales of Top Anti-Alzheimer’s Disease Products in 2011
Table 27: Sales of Top Anti-Migraine Products in 2011
Table 28: Sales of Top Antipsychotic Products in 2011
Table 29: Sales of Top Anti-Parkinson’s Disease Products in 2011
Table 30: Sales of Top Hypnotics & Sedatives in 2011
Table 31: Sales of Top Psychostimulant Products in 2011
Table 32: Levadex Clinical Trial Data
Table 33: Sales Forecast of Leading CNS Drug Classes (in USD Million), 2011-2017
Table 34: Sales Forecast for Leading CNS Brands (in USD Million), 2011-2017
Table 35: Top Players in the CNS Market in 2011
Table 1: Epidemiology of ADHD in Adults, 2011-2017
Table 2: Epidemiology of ADHD in Children, 2011-2017
Table 3: Epidemiology of ADHD in Adults, 2011-2017
Table 4: Epidemiology of ADHD in Children, 2011-2017
Table 5: Prevalence of Alzheimer’s Disease in Select Countries, 2011
Table 6: Epidemiology of Alzheimer's Disease, 2011-2017
Table 7: Prevalence of Epilepsy in Select Countries, 2011
Table 8: Epidemiology of Epilepsy, 2011-2017
Table 9: Prevalence of Insomnia in Select Countries, 2011
Table 10: Epidemiology of Insomnia, 2011-2017
Table 11: Prevalence of Major Depressive Disorders in Select Countries, 2011
Table 12: Epidemiology of Major Depressive Disorders, 2011-2017
Table 13: Prevalence of Migraine in Select Countries, 2011
Table 14: Epidemiology of Migraine, 2011-2017
Table 15: Prevalence of Parkinson’s Disease in Select Countries, 2011
Table 16: Epidemiology of Parkinson’s Disease, 2011-2017
Table 17: Prevalence of Schizophrenia in Select Countries, 2011
Table 18: Epidemiology of Schizophrenia, 2011-2017
Table 19: Performance of the CNS Market by Region (2006-2011)
Table 20: Top 10 CNS Products in 2011
Table 21: Patent Expiries of Key CNS Drugs/Brands
Table 22: Global CNS Pipeline
Table 23: Performance of Various CNS Drug Classes, 2011
Table 24: Sales of Top Antidepressant Products in 2011
Table 25: Sales of Top Anti-epileptics Products in 2011
Table 26: Sales of Top Anti-Alzheimer’s Disease Products in 2011
Table 27: Sales of Top Anti-Migraine Products in 2011
Table 28: Sales of Top Antipsychotic Products in 2011
Table 29: Sales of Top Anti-Parkinson’s Disease Products in 2011
Table 30: Sales of Top Hypnotics & Sedatives in 2011
Table 31: Sales of Top Psychostimulant Products in 2011
Table 32: Levadex Clinical Trial Data
Table 33: Sales Forecast of Leading CNS Drug Classes (in USD Million), 2011-2017
Table 34: Sales Forecast for Leading CNS Brands (in USD Million), 2011-2017
Table 35: Top Players in the CNS Market in 2011
